CJC-1295 — Peptide Dosing Protocols reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
CJC-1295 No DAC Peptide Dosing Guide: Mod GRF, Timing & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols CJC-1295 No DAC Dosing Guide: Mod GRF, Timing & Safety (2026) Protocol / Research Dosing Guide CJC-1295 No DAC Dosing Guide: Mod GRF, Timing & Safety (2026) An evidence-based CJC-1295 No DAC protocol guide covering Mod GRF 1-29 dosing structure, injection timing, reconstitution math, Ipamorelin pairing, and safety considerations for this short-acting GHRH analog peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners CJC-1295 No DAC Supply View CJC-1295 No DAC Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status CJC-1295 Comparisons Related Protocols Blood Tests FAQ References CJC-1295 No DAC Quick Start CJC-1295 No DAC, also called Modified GRF 1-29 or Mod GRF 1-29 , is a short-acting copy of the body's own growth-hormone-releasing hormone (GHRH). It tells the pituitary gland to release a short burst of growth hormone, then clears the body in about 30 minutes.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (9) · phenotypes (0)
evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference
Findings (163) · awaiting review (117)
monitoring · pending
Optional Monitoring guidance is GH-axis pathway-based and extrapolated from human GHRH analog data and GH/IGF physiology.
regulatory · pending
Status Not FDA-approved.
regulatory · pending
CJC-1295 No DAC is not approved by the FDA for human use.
dosing · pending
This no-DAC page covers dose timing and setup.
safety · pending
It covers effects, studies, safety notes, and legal status.
mechanism · pending
No similar signal has been reported for the No DAC variant.
mechanism · pending
GHRH receptor only Selective for GHRH receptors.
monitoring · pending
CJC-1295 No DAC Timeline & What to Monitor There is no la
mechanism · pending
Does not directly activate the ghrelin pathway.
outcome · pending
rge outcome trial that maps response timelines for the No DAC variant.
dosing · pending
Most reported effects pass within 30–60 minutes of a dose.
dosing · pending
Q4: How do you reconstitute a 10 mg CJC-1295 No DAC vial?
dosing · pending
Tingling or numbness in the hands, sometimes linked to higher single doses.
mechanism · pending
They use the same receptor but produce very different signaling patterns.
dosing · pending
The default setup is a 10 mg vial with 3 mL bacteriostatic water, which gives 3,333 mcg/mL.
mechanism · pending
Ipamorelin works through the ghrelin receptor.
dosing · pending
CJC-1295 No DAC Peptide Dosing Guide: Mod GRF, Timing & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols CJC-1295 No DAC Dosing Guide: Mod GRF, Timing & Safety (2026) Protocol / Research Dosing Guide CJC-1295 No DAC Dosing Guide: Mod GRF, Timing & Safety (2026) An evidence-based CJC-1295 No DAC protocol guide covering Mod GRF 1-29 dosing structure, injection timing, reconstitution math, Ipamorelin pairing, and safety considerations for this short-acting GHRH analog peptide.
dosing · pending
By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners CJC-1295 No DAC Supply View CJC-1295 No DAC Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status CJC-1295 Comparisons Related Protocols Blood Tests FAQ References CJC-1295 No DAC Quick Start CJC-1295 No DAC, also called Modified GRF 1-29 or Mod GRF 1-29 , is a short-acting copy of the body's own growth-hormone-releasing hormone (GHRH).
regulatory · pending
CJC-1295 No DAC is not FDA-approved and is used only in research-reference contexts.
dosing · pending
Each dose creates one short pulse, then fades.
dosing · pending
Common dose range 100–300 mcg per injection, 1–3 times daily in fasted windows.
dosing · pending
Default vial setup 10 mg vial with 3 mL bacteriostatic water gives a clean 3,333 mcg/mL working solution.
dosing · pending
Upper community range Protocol-dependent Up to 300 mcg, up to 3x daily Higher single doses tend to add side effects without bigger GH gains.
dosing · pending
Not a dosing recommendation.
dosing · pending
CJC-1295 No DAC Dosing Protocol & Schedule Most CJC-1295 No DAC research protocols start low and increase slowly.
dosing · pending
The short half-life means each dose is mostly independent, so timing the dose around fasted windows usually matters more than chasing a higher number.
dosing · pending
Typical Titration Pattern Common CJC-1295 No DAC titration framework Phase Initiation Window Weeks 1–2 Dose per injection 100 mcg, once daily Notes Pre-bed in a fasted window.
dosing · pending
Phase Early escalation Window Weeks 3–4 Dose per injection 150 mcg, once daily Notes Increase by 50 mcg only if initiation is tole
dosing · pending
Phase Therapeutic range Window Weeks 5–8 Dose per injection 200 mcg, once daily Notes Common maintenance level in community protocols.
dosing · pending
Phase Advanced range Window Weeks 5–12+ Dose per injection 200–300 mcg, 1–2x daily Notes Often split between morning fasted and pre-bed windows.
dosing · pending
Phase Upper community range Window Protocol-dependent Dose per injection Up to 300 mcg, up to 3x daily Notes Higher single doses tend to add side effects without bigger GH gains.
dosing · pending
Phase Window Dose per injection Notes Initiation Weeks 1–2 100 mcg, once daily Pre-bed in a fasted window.
dosing · pending
Early escalation Weeks 3–4 150 mcg, once daily Increase by 50 mcg only if initiation is tolerated.
dosing · pending
Therapeutic range Weeks 5–8 200 mcg, once daily Common maintenance level in community protocols.
dosing · pending
Advanced range Weeks 5–12+ 200–300 mcg, 1–2x daily Often split between morning fasted and pre-bed windows.
dosing · pending
Why Frequency Often Beats a Higher Single Dose Researchers describe a saturation point : roughly 100 mcg seems to fill the available pituitary receptors for a single pulse.
dosing · pending
Pushing past that with a larger single dose does not usually create a much larger growth hormone burst.
dosing · pending
lanning frameworks add a second daily injection before they raise the size of one dose.
mechanism · pending
Food, especially carbs, can dampen the GH pulse because insulin blunts GH signaling.
dosing · pending
Pre-bed dosing lines up with the body's largest natural GH pulse during deep sleep.
Processing
Processed into 26 searchable sections.